The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
A Phase 3 Trial of l -Glutamine in Sickle Cell Disease
Open accessAbstract
BACKGROUND: Oxidative stress contributes to the complex pathophysiology of sickle cell disease. Oral therapy with pharmaceutical-grade l-glutamine (USAN, glutamine) has been shown to increase the proportion of the reduced form of nicotinamide adenine dinucleotides in sickle cell erythrocytes, which probably reduces oxidative stress and could result in fewer episodes of sickle cell-related pain. METHODS: -thalassemia and a history of two or more pain crises during the previous year. Patients who were receiving hydroxyurea at a dose that had been stable for at least 3 months before screening continued that therapy through the 48-week treatment period. RESULTS: A total of 230 patients (age range, 5 to 58 years; 53.9% female) were randomly assigned, in a 2:1 ratio, to receive l-glutamine (152 patients) or placebo (78 patients). The patients in the l-glutamine group had significantly fewer pain crises than those in the placebo group (P=0.005), with a median of 3.0 in the l-glutamine group and 4.0 in the placebo group. Fewer hospitalizations occurred in the l-glutamine group than in the placebo group (P=0.005), with a median of 2.0 in the l-glutamine group and 3.0 in the placebo group. Two thirds of the patients in both trial groups received concomitant hydroxyurea. Low-grade nausea, noncardiac chest pain, fatigue, and musculoskeletal pain occurred more frequently in the l-glutamine group than in the placebo group. CONCLUSIONS: Among children and adults with sickle cell anemia, the median number of pain crises over 48 weeks was lower among those who received oral therapy with l-glutamine, administered alone or with hydroxyurea, than among those who received placebo, with or without hydroxyurea. (Funded by Emmaus Medical; ClinicalTrials.gov number, NCT01179217 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Partial residuals for the proportional hazards regression model
SCHOENFELD, D. (1982) · Biometrika · doi:10.1093/biomet/69.1.239 · Cited by 3,111
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease
Vichinsky, E. P., Neumayr, L. D., Earles, A. N., Williams, R., Lennette, E. T., Dean, D., Nickerson, B., Orringer, E., McKie, V., Bellevue, R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422502 · Cited by 1,234
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Crizanlizumab for the prevention of pain crises in sickle cell disease.
Ataga, K. I., Kutlar, A., Kanter, J., Liles, D., Cancado, R., Friedrisch, J., Guthrie, T. H., Knight-Madden, J., Alvarez, O. A., Gordeuk, V. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611770 · Cited by 914
Self-citationZiegler, T. R., Young, L. S., Benfell, K., Scheltinga, M., Hortos, K., Bye, R., Morrow, F. D., Jacobs, D. O., Smith, R. J., Antin, J. H., et al. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-10-821 · Cited by 756
Hebbel, R. P., Boogaerts, M. A. B., Eaton, J. W., & Steinberg, M. H. (1980) · New England Journal of Medicine · doi:10.1056/nejm198005013021803 · Cited by 518
Nur, E., Biemond, B. J., Otten, H., Brandjes, D. P., Schnog, J. B., & the CURAMA Study Group (2011) · American Journal of Hematology · doi:10.1002/ajh.22012 · Cited by 248
Role of oxidative stress in the pathogenesis of sickle cell disease
Chirico, E. N., & Pialoux, V. (2012) · IUBMB Life · doi:10.1002/iub.584 · Cited by 227
Morris, C. R., Suh, J. H., Hagar, W., Larkin, S., Bland, D. A., Steinberg, M. H., Vichinsky, E. P., Shigenaga, M., Ames, B., Kuypers, F. A., et al. (2008) · Blood · doi:10.1182/blood-2007-04-081703 · Cited by 191
Self-citationPulmonary Hypertension and Cor Pulmonale during Severe Acute Chest Syndrome in Sickle Cell Disease
Mekontso Dessap, A., Leon, R., Habibi, A., Nzouakou, R., Roudot-Thoraval, F., Adnot, S., Godeau, B., Galacteros, F., Brun-Buisson, C., Brochard, L., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200710-1606oc · Cited by 170
Clinically silent primary adrenal lymphoma: A case report and review of the literature
Wang, J., Sun, N. C. J., Renslo, R., Chuang, C., Tabbarah, H. J., Barajas, L., & French, S. W. (1998) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199806)58:2<117::aid-ajh5>3.0.co;2-v · Cited by 110
Niihara, Y., Matsui, N. M., Shen, Y. M., Akiyama, D. A., Johnson, C. S., Sunga, M. A., Magpayo, J., Embury, S. H., Kalra, V. K., Cho, S., et al. (2005) · BMC Hematology · doi:10.1186/1471-2326-5-4 · Cited by 86
Self-citationSide Effects of Long‐Term Glutamine Supplementation
Holeček, M. (2012) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607112460682 · Cited by 79
Peters-Lawrence, M. H., Bell, M. C., Hsu, L. L.-Y., Osunkwo, I., Seaman, P., Blackwood, M., Guillaume, E., Bellevue, R., Krishnamurti, L., Smith, W. R., et al. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.11.018 · Cited by 74
Self-citationZerez, C., Lachant, N., Lee, S., & Tanaka, K. (1988) · Blood · doi:10.1182/blood.v71.2.512.512 · Cited by 63
Clinical correlates of acute pulmonary events in children and adolescents with sickle cell disease
Paul, R. N., Minniti, C. P., Nouraie, M. S., Luchtman‐Jones, L., Campbell, A., RANA, S. R., Onyekwere, O. C., Darbari, D. S., Ajayi, O., Arteta, M., et al. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12118 · Cited by 38
Self-citationGlutamine Supplementation in Sick Children: Is It Beneficial?
Mok, E., & Hankard, R. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2011/617597 · Cited by 35
Pyridine Nucleotide Redox Potential in Erythrocytes of Saudi Subjects with Sickle Cell Disease
Al‐Ali, A. K. (2002) · Acta Haematologica · doi:10.1159/000063062 · Cited by 13
Cited by
Identification of bioactive metabolites using activity metabolomics
Rinschen, M. M., Ivanisevic, J., Giera, M., & Siuzdak, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0108-4 · Cited by 1,008
Connelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease
Vichinsky, E., Hoppe, C. C., Ataga, K. I., Ware, R. E., Nduba, V., El-Beshlawy, A., Hassab, H., Achebe, M. M., Alkindi, S., Brown, R. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903212 · Cited by 624
Self-citationKavanagh, P. L., Fasipe, T. A., & Wun, T. (2022) · JAMA · doi:10.1001/jama.2022.10233 · Cited by 478
Brandow, A. M., Carroll, C. P., Creary, S., Edwards-Elliott, R., Glassberg, J., Hurley, R. W., Kutlar, A., Seisa, M., Stinson, J., Strouse, J. J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001851 · Cited by 456
Metadata
- Authors
- Niihara, Y., Miller, S. T., Kanter, J., Lanzkron, S., Smith, W. R., Hsu, L. L., Gordeuk, V. R., Viswanathan, K., Sarnaik, S., Osunkwo, I., Guillaume, E., Sadanandan, S., Sieger, L., Lasky, J. L., Panosyan, E. H., Blake, O. A., New, T. N., Bellevue, R., Tran, L. T., Razon, R. L., Stark, C. W., Neumayr, L. D., & Vichinsky, E. P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-07-19
- Volume
- 379
- Issue
- 3
- Pages
- 226-235
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2883955692
- Cited by
- 563
- References
- 19
- FWCI
- 26.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.